Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Clinical and molecular study of radiation-induced gliomas

K. Trkova, D. Sumerauer, A. Bubenikova, L. Krskova, A. Vicha, M. Koblizek, J. Zamecnik, B. Jurasek, M. Kyncl, B. Malinova, B. Ondrova, DTW. Jones, M. Sill, M. Strnadova, L. Stolova, A. Misove, V. Benes, M. Zapotocky

. 2024 ; 14 (1) : 3118. [pub] 20240207

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24007181

Grant support
204220 Grantová Agentura, Univerzita Karlova
PRIMUS/19/MED/06 Grantová Agentura, Univerzita Karlova
LX22NPO5102 European Union
MH CZ-DRO,00064203 University Hospital Motol
NU21-07-00419 Ministerstvo Zdravotnictví Ceské Republiky
NU23-08-00460 Ministerstvo Zdravotnictví Ceské Republiky

In this study, we provide a comprehensive clinical and molecular biological characterization of radiation-induced gliomas (RIG), including a risk assessment for developing gliomas. A cohort of 12 patients who developed RIG 9.5 years (3-31 years) after previous cranial radiotherapy for brain tumors or T-cell acute lymphoblastic leukemia was established. The derived risk of RIG development based on our consecutive cohort of 371 irradiated patients was 1.6% at 10 years and 3.02% at 15 years. Patients with RIG glioma had a dismal prognosis with a median survival of 7.3 months. We described radiology features that might indicate the suspicion of RIG rather than the primary tumor recurrence. Typical molecular features identified by molecular biology examination included the absence of Histon3 mutation, methylation profile of pedHGG-RTK1 and the presence of recurrent PDGFRA amplification and CDKN2A/B deletion. Of the two long-term surviving patients, one had gliomatosis cerebri, and the other had pleomorphic xanthoastrocytoma with BRAF V600E mutation. In summary, our experience highlights the need for tissue diagnostics to allow detailed molecular biological characterization of the tumor, differentiation of the secondary tumor from the recurrence of the primary disease and potentially finding a therapeutic target.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007181
003      
CZ-PrNML
005      
20240423155756.0
007      
ta
008      
240412s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-024-53434-0 $2 doi
035    __
$a (PubMed)38326438
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Trkova, Katerina $u Prague Brain Tumor Research Group, Second Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic $u Center for Pediatric Neuro-Oncology, University Hospital Motol, V Uvalu 84 , 15006, Prague 5, Czech Republic $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University Prague and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic
245    10
$a Clinical and molecular study of radiation-induced gliomas / $c K. Trkova, D. Sumerauer, A. Bubenikova, L. Krskova, A. Vicha, M. Koblizek, J. Zamecnik, B. Jurasek, M. Kyncl, B. Malinova, B. Ondrova, DTW. Jones, M. Sill, M. Strnadova, L. Stolova, A. Misove, V. Benes, M. Zapotocky
520    9_
$a In this study, we provide a comprehensive clinical and molecular biological characterization of radiation-induced gliomas (RIG), including a risk assessment for developing gliomas. A cohort of 12 patients who developed RIG 9.5 years (3-31 years) after previous cranial radiotherapy for brain tumors or T-cell acute lymphoblastic leukemia was established. The derived risk of RIG development based on our consecutive cohort of 371 irradiated patients was 1.6% at 10 years and 3.02% at 15 years. Patients with RIG glioma had a dismal prognosis with a median survival of 7.3 months. We described radiology features that might indicate the suspicion of RIG rather than the primary tumor recurrence. Typical molecular features identified by molecular biology examination included the absence of Histon3 mutation, methylation profile of pedHGG-RTK1 and the presence of recurrent PDGFRA amplification and CDKN2A/B deletion. Of the two long-term surviving patients, one had gliomatosis cerebri, and the other had pleomorphic xanthoastrocytoma with BRAF V600E mutation. In summary, our experience highlights the need for tissue diagnostics to allow detailed molecular biological characterization of the tumor, differentiation of the secondary tumor from the recurrence of the primary disease and potentially finding a therapeutic target.
650    _2
$a lidé $7 D006801
650    _2
$a protoonkogenní proteiny B-Raf $x genetika $7 D048493
650    12
$a gliom $x genetika $x radioterapie $7 D005910
650    12
$a nádory mozku $x genetika $x radioterapie $7 D001932
650    12
$a astrocytom $x patologie $7 D001254
650    _2
$a mutace $7 D009154
655    _2
$a časopisecké články $7 D016428
700    1_
$a Sumerauer, David $u Prague Brain Tumor Research Group, Second Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic $u Center for Pediatric Neuro-Oncology, University Hospital Motol, V Uvalu 84 , 15006, Prague 5, Czech Republic $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University Prague and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic
700    1_
$a Bubenikova, Adela $u Department of Neurosurgery, Second Faculty of Medicine, Charles University Prague and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic
700    1_
$a Krskova, Lenka $u Prague Brain Tumor Research Group, Second Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic $u Center for Pediatric Neuro-Oncology, University Hospital Motol, V Uvalu 84 , 15006, Prague 5, Czech Republic $u Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University Prague and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic
700    1_
$a Vicha, Ales $u Prague Brain Tumor Research Group, Second Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic $u Center for Pediatric Neuro-Oncology, University Hospital Motol, V Uvalu 84 , 15006, Prague 5, Czech Republic $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University Prague and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic
700    1_
$a Koblizek, Miroslav $u Prague Brain Tumor Research Group, Second Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic $u Center for Pediatric Neuro-Oncology, University Hospital Motol, V Uvalu 84 , 15006, Prague 5, Czech Republic $u Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University Prague and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic
700    1_
$a Zamecnik, Josef $u Prague Brain Tumor Research Group, Second Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic $u Center for Pediatric Neuro-Oncology, University Hospital Motol, V Uvalu 84 , 15006, Prague 5, Czech Republic $u Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University Prague and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic
700    1_
$a Jurasek, Bruno $u Department of Radiology, Second Faculty of Medicine, Charles University Prague and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic
700    1_
$a Kyncl, Martin $u Center for Pediatric Neuro-Oncology, University Hospital Motol, V Uvalu 84 , 15006, Prague 5, Czech Republic $u Department of Radiology, Second Faculty of Medicine, Charles University Prague and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic
700    1_
$a Malinova, Bela $u Department of Oncology, Second Faculty of Medicine, Charles University Prague and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic
700    1_
$a Ondrova, Barbora $u Proton Therapy Center Czech, Budínova 1a, 180 00, Prague, Czech Republic
700    1_
$a Jones, David T W $u Division of Pediatric Glioma Research, Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany $u National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany $u German Cancer Research Center (DKFZ), Heidelberg, Germany
700    1_
$a Sill, Martin $u Division of Pediatric Glioma Research, Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany $u National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany $u German Cancer Research Center (DKFZ), Heidelberg, Germany
700    1_
$a Strnadova, Martina $u Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University Prague and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic
700    1_
$a Stolova, Lucie $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University Prague and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic
700    1_
$a Misove, Adela $u Prague Brain Tumor Research Group, Second Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic $u Center for Pediatric Neuro-Oncology, University Hospital Motol, V Uvalu 84 , 15006, Prague 5, Czech Republic $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University Prague and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic
700    1_
$a Benes, Vladimir $u Center for Pediatric Neuro-Oncology, University Hospital Motol, V Uvalu 84 , 15006, Prague 5, Czech Republic $u Department of Neurosurgery, Second Faculty of Medicine, Charles University Prague and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic
700    1_
$a Zapotocky, Michal $u Prague Brain Tumor Research Group, Second Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic. michal.zapotocky@fnmotol.cz $u Center for Pediatric Neuro-Oncology, University Hospital Motol, V Uvalu 84 , 15006, Prague 5, Czech Republic. michal.zapotocky@fnmotol.cz $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University Prague and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic. michal.zapotocky@fnmotol.cz
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 14, č. 1 (2024), s. 3118
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38326438 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155753 $b ABA008
999    __
$a ok $b bmc $g 2081270 $s 1216948
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 14 $c 1 $d 3118 $e 20240207 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
GRA    __
$a 204220 $p Grantová Agentura, Univerzita Karlova
GRA    __
$a PRIMUS/19/MED/06 $p Grantová Agentura, Univerzita Karlova
GRA    __
$a LX22NPO5102 $p European Union
GRA    __
$a MH CZ-DRO,00064203 $p University Hospital Motol
GRA    __
$a NU21-07-00419 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a NU23-08-00460 $p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20240412

Find record

Citation metrics

Archiving options